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Abstract
Background
Blood infections are serious complex conditions that generally require rapid diagnosis and
treatment. The big challenge is to reduce the time necessary to make a diagnosis with cur-
rent clinical microbiological methods so as to improve the treatment given to patients.
Methods
In this study, we assess for the first time the Sepsis Flow Chip assay, which is a novel diag-
nostic assay for simultaneous rapid-detection of the vast majority of bloodstream patho-
gens, including Gram-positive and Gram-negative bacteria and fungi, in the same assay,
and for the detection of most common antibiotic resistance genes. The SFC assay is based
on multiplex PCR and low density DNA arrays.
Results
Positive blood cultures from 202 consecutive bacteremia patients were analyzed by SFC
assay and the results were compared with the results obtained by the gold standard meth-
odology used in clinical microbiology diagnostic laboratories (EUCAST guidelines). SFC
assay overall sensitivity and specificity for bacterial identification were 93.3% and 100%
respectively and sensitivity and specificity for the identification of antibiotic genetic resis-
tance determinants were 93.6% and 100% respectively.
Conclusions
This is the first evaluation of SFC assay in clinical samples. This new method appears to be
very promising by combining the high number of distinct pathogens and genetic resistance
determinants identified in a single assay. Further investigations should be done to evaluate
the usefulness of this assay in combination with clinical multidisciplinary groups
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(stewardship), in order for the results to be applied appropriately to the management of
patients‘infectious processes.
Introduction
Bloodstream infections are one of the most serious infectious diseases, with mortality rates of
around 30–50% [1]. Factors that make bloodstream infections more difficult to manage and
treat include an aging population, chronic diseases, immunosuppression, and most impor-
tantly, the increase in antibiotic resistance [2].
Although causative pathogens of bloodstream infections are consistent between studies [3],
the empirical treatments used are often inappropriate [4]. This has serious clinical implications
for the patient [4,5] since treatment response is directly related to the time that elapses before
the appropriate antimicrobial therapy is administered. In some cases, the mortality rate can
increase [6] between 6 and 10% for each hour of delay.
The conventional microbiological methods available nowadays for identifying the microor-
ganisms causing bloodstream infections are too slow. Preliminary result based on Gram stain-
ing once the blood culture turns positive can be obtained in less than an hour but around 18 to
72 hours may be needed in order to get an accurate result including the antibiotic susceptibility
pattern of the pathogen involved. In addition to the risk of administering incorrect treatment,
this delay in diagnosis favors the use of broad spectrum antibiotics, implying a high healthcare
cost, and the selection of antibiotic-resistant bacteria [1,3,4]. The introduction of new systems
of microbiological diagnosis in clinical microbiology laboratories such as matrix-assisted mass
spectrometry (MALDI-TOF) [7] or real time PCR [8] have revolutionized microbiological
diagnosis producing reliable results in short periods of time. However, these new approaches
have significant limitations such as the inability to detect a wide range of antibiotic resistance
markers in a same test [9,10], impacting this fact in time to diagnosis.
Sepsis Flow Chip (SFC), (Master Diagnostica, Granada, Spain) is a novel microarray-based
diagnostic assay for simultaneous rapid detection of microorganisms causing bloodstream
infection and their most important antibiotic resistance markers directly from positive blood
cultures in three hours.
The aim of this study was to evaluate for the first time the diagnostic capability of the SFC
assay with a collection of microorganisms with a wide variety of genetic resistance determi-
nants and with positive blood cultures samples.
Material and methods
SFC assay
SFC (Master Diagnostica, Granada, Spain) is a DNA microarray based-assay approved by the
European Economic Area as a suitable device for in vitro diagnosis (CE IVD). SFC assay is
based on a multiplex PCR amplification using biotinylated primers followed by an automatic
reverse hybridization in membrane containing specific probes for detecting the most impor-
tant pathogens associated with bloodstream infections and the most important genetic resis-
tance determinants in these microorganisms (Table 1).
Positive signals are visualized via a colorimetric immunoenzymatic reaction in a chip mem-
brane (Fig 1) by the HS24 hybridization platform. The HS24 hybridization platform has a
built-in camera that captures the image of the chip and then is analized in the platform by the
hybrisoft software which identifies the dot pattern that appears on the membrane. Each dot
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pattern is associated with a microorganism and genetic resistance determinants and the hybri-
soft software provide to the user a result. The assay can detect at the species level 12 bacteria
and 1 yeast, at genus level 4 bacterial genus and under the generic category “Enterobacteria-
ceae” all Enterobacteriaceae other than E. coli, K. pneumoniae, M. morganii, Proteus sp. and S.
marcescens. SFC assay detects the most important genetic resistance determinants involved in
resistance to methicillin and vancomycin in Gram-positive pathogens and determinants
related to ß-lactam resistance mechanisms such as ESBLs and carbapenemase production in
Gram-negative bacteria (Table 1). The test is performed directly from a positive blood culture
using a minimum volume (10 μl).
Pre-clinical evaluation of the SFC assay
In order to confirm the ability of the system to detect all the microorganisms and their genetic
resistance determinants included in the panel, we tested a collection of 109 bacterial strains
and 9 fungi strains (S1 Table) in monomicrobial or polymicrobial samples (S2 Table). The
microorganisms and its genetic resitance determinants identification were previously charac-
terized phenotypically and then confirmed genotypically. Genotypic identification were car-
ried out by amplification of the 16S rRNA gene by PCR with 16S rRNA universal primers 27F
and 1392R followed by DNA sequencing [11], 16s rDNA sequences were assigned using ribo-
somal database project classifier with the 16S rRNA database (https://rdp.cme.msu.edu).
Table 1. Clinical pathogens and genetic resistant determinants detected by Sepsis Flow Chip assay.
Pathogen Identification Genetic Resistance Determinants
Gram-positive Bacteria -
Streptococcus pneumoniae -
Streptococcus agalactiae -
Streptococcus spp. -
Staphylococcus aureus mecA
Staphylococcus spp.
Enterococcus spp. vanA/B
Listeria monocytogenes -
Gram-negative Bacteria
Stenotrophomonas
maltophilia
blaCTX, blaSHV, blaSME, blaKPC, blaNMC/IMI, blaGES, blaIMP, blaGIM,
blaVIM, blaSPM, blaSIM, blaNDM, blaOXA-23, blaOXA-24, blaOXA-48,
blaOXA-51 and blaOXA-58Serratia marcescens
Escherichia coli
Klebsiella pneumoniae
Morganella morganii
Proteus spp.
Enterobacteriaceae
Acinetobacter baumannii
Pseudomonas aeruginosa
Neisseria meningitidis
Fungi
Candida albicans -
Identification panel of SFC assay including gram-positive, gram-negative and fungi pathogens. Genetic
resistance determinants identification include the main mechanisms for gram-positive pathogens and the
main ESBL and carbapenemases in gram-negative pathogens.
https://doi.org/10.1371/journal.pone.0177627.t001
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Genotypic characterization of genetic resistance determinants for methicillin resistant
Staphylococcus spp. and vancomycin resistant Enterococcus spp. were carried out with Xpert
MRSA and Xpert VanA/vanB assay respectively (Cepheid, California, USA). Genotypic char-
acterization of genetic resistance determinants for extended spectrum ß-lactamase (ESBL) and
class A and B carbapenemase producers bacterial strains, were carried out by Real Time PCR
[12,13]. Class D carbapenemase producers strains characterization were carried out by con-
ventional PCR and DNA sequencing [14].
For pre-clinical evaluation of SFC assay, one single colony of each strain was re-suspended
in distilled water at a concentration of 0.5 McFarland (1.5108 UFC/ml) and 5 ml were inocu-
lated in a Bactec bottle. Each sample was then manipulated as a positive blood culture follow-
ing the manufacturer’s instruction prior to analysis by SFC assay. Also combinations of some
samples were used for the evaluation of SFC in polymicrobial samples (S2 Table).
Clinical evaluation of the SFC assay
Further, a total of 202 positive blood cultures obtained consecutively from unique patients
with bacteremia were included in the evaluation of the SFC assay. Blood cultures from patients
with bacteremia were collected in Bactec plus/F aerobic and anaerobic culture bottles (Becton
Dickinson, New Jersey, USA) and incubated on BD BACTECTM 9240 (Becton Dickinson,
New Jersey, USA). When the BD BACTEC system detected a positive sample, the blood cul-
ture bottle was removed from the system and analyzed in parallel by our standard microbio-
logical methods and by SFC assay. Only one blood culture bottle per patient was analyzed by
Fig 1. Sepsis Flow Chip device. Multi Drug Resistant A. baumannii carbapenemase producer strain
analyzed by SFC assay. All target probes are by duplicate on the array and a result is considered as positive
result if both signals are detected. Positive probes detected: Biotin Control (BC), Inner Control (IC), A.
baumannii (ABAU), blaOXA-23 (OXA23) and blaOXA-51 (OXA51). The image is enlarged x10 regarding the
actual size of the chip.
https://doi.org/10.1371/journal.pone.0177627.g001
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SFC regardless of whether it was an aerobic or anaerobic bottle. An aliquot of 500 μl of each
blood culture sample included in the study was preserved at -20˚C for future determinations
in case discrepant results were obtained with the different methodologies and reproducibility
assays.
According to our standard microbiological diagnostic protocols, positive blood cultures
were processed for Gram staining and subcultured onto different culture media. The microor-
ganisms were identified using MALDI-TOF (Burker Daltonics, Bremen, Germany) and this
was complemented by biochemical identification and susceptibility testing by WalkAway
(Beckman, San Francisco, USA) following the EUCAST guidelines [15] for analysis of antibi-
otic susceptibility. Confirmatory susceptibility studies were performed by E-test and by molec-
ular methods. Methicillin resistant Staphylococci were confirmed by Xpert MRSA. Bacterial
strains suspected of being carriers of ESBL or carbapenemases were confirmed by molecular
methods previously described [12].
Positive blood cultures were processed in parallel by SFC assay. A volume of 10 μl of posi-
tive blood culture was diluted 1/10 with distilled water to a final volume of 100 μl and a volume
of 4 μl of this dilution was used to perform the assay. Amplification reactions were carried out
in a thermal cycler (Veriti Thermal Cycler, Applied Biosystems, California, USA) following
manufacturer’s instructions, reverse hybridization and analysis of the results were automati-
cally conducted with the hybriSpot HS24 platform (Master Diagnostica, Granada, Spain). The
time necessary to obtain a result from a positive blood culture with SFC assay is about three
hours and the platform can process up to 24 samples simultaneously.
Once the study was completed, 20 samples randomly selected from the preserved blood cul-
ture collection were reanalyzed in order to study the reproducibility of the results obtained by
SFC assay.
For the evaluation of the SFC assay in positive blood cultures, sensitivity and specificity
with 95% confidence intervals and concordance between conventional methods and SFC assay
were calculated using SPSS v 17.0. The samples used for this study were surplus of clinical
diagnosis and the data were analyzed anonymously, according to the law of biomedical
research; it was not necessary to obtain informed consent. This study was approved by the
local ethical committee of the Hospital General Universitario of Alicante (CEIC PI2015/39).
Results
Pre-clinical evaluation results
When SFC assay was tested using a collection of bacteria and fungi in monomicrobial samples,
including multiresistant bacterial strains and representing all the species and genetic resistance
determinants included in the test, it was seen to identify all the bacteria and C. albicans strains.
Bacterial strains and other Candida spp. as C. parapsilosis, C. tropicalis, C. krusei and C. glabrata
not included in the SFC detection panel were not detected as was expected.
SFC assay also detected 100% of bacterial strains (31/31) with genetic resistance determi-
nants in Gram-positive bacteria and 98% (55/56) of gram-negative bacteria. The assay identi-
fied 3 Enterococcus sp. Strains (1 carrying vanA and 2 with vanB genes); regarding mecA, the
assay detected correctly 28 strains (3 corresponding to S. aureus and 25 corresponding to oth-
ers Staphylococcus spp). Similarly, SFC detected correctly 100% of ESBLs producers strains car-
rying blaCTX-M and/or blaSHV (28/28). Furthermore, the assay was able to detect 97% (32/
33) of carbapenemase producers in strains with one or even two carbapenemases or strains
with combinations of carbapenemase and ESBL. Only one carbapenemase (blaIMP-4) in a K.
pneumoniae isolate was not detected. (S1 Table).
SFC assay for the diagnosis of blood infections
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In polymicrobial samples the identification of all bacterial strains tested was not as good as
in monomicrobial samples, the assay showed some limitations in samples with more than 3 of
Enterobacteriaceae members. Regarding to the detection of genetic resistance determinants in
polymicrobial samples, the assay showed no limitations in samples up to three microorgan-
isms. The results of the tests performed with SFC on polymicrobial samples are shown on
S2 table.
Clinical evaluation results
Further, a total of 202 blood cultures containing 225 organisms were included in the study.
One hundred and eighty eight isolates were in monomicrobial blood cultures and 37 in poly-
microbial blood cultures. Of the isolates identified by MALDI-TOF and WalkAway 51.1%
(115/225) were gram positive, 46.2% (104/225) were gram negative and 2.6% (6/225) were
yeasts.
The gram-positive microorganisms most frequently identified by SFC assay were Staphylo-
coccus spp. with 83 identifications, 13 of which were identified as S. aureus. By MALDI-TOF
and WalkAway 83 isolates of Staphylococcus spp. were identified and distributed as follows:
S. epidermidis (46/83), S. hominis (21/83) S. aureus (13/83), S. capitis (2/83) and S. haemolyticus
(1/83). These results showed 100% concordance between our standard microbiological diag-
nostic protocols and SFC assay.
SFC assay also detected the presence of Streptococcus spp. in 15 blood cultures, and in 9 of
these samples S. pneumoniae was identified. By MALDI-TOF and WalkAway Streptococcus
spp. were isolated from 17 blood cultures; these isolates were identified as S. pneumoniae (9/
17), S. gallolyticus (3/17), S. parasanguinis (1/17), S. intermedius (1/17), S. viridans (1/17), S. sal-
ivarius (1/17) and S. oralis (1/17). Two blood cultures harbouring S. parasanguinis and S. viri-
dans were not detected by SFC assay. In identifying Streptococcus spp. the overall concordance
between our standard microbiological diagnostic protocols and SFC assay was 88% (15/17)
and reached 100% (9/9) for S. pneumoniae.
Enterococcus spp. at the genus level were also detected in 14 blood cultures by SFC assay and
by MALDI-TOF and WalkAway, thus, showing a concordance between methodologies of
100% (14/14). These isolates were distributed among the species E. faecalis (13/14) and E. fae-
cium (1/14).
Only one blood culture with L. monocytogenes was identified by SFC assay showing 100%
concordance with our standard microbiological diagnostic protocols.
As for the detection of gram-negative microorganisms in positive blood cultures, the
SFC assay detected at the species level the presence of Escherichia coli, Klebsiella pneumo-
niae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Serratia marcescens, Acineto-
bacter baumannii and Morganella morganii. Proteus spp. and other Enterobacteriaceae
were identified under the category “Enterobacteriaceae”. According to MALDI-TOF and
WalkAway identifications, SFC assay correctly identified 100% of blood cultures containing
E. coli (56/56), K. pneumoniae (15/15), P. aeruginosa (4/4) P. mirabilis (3/3), A. baumannii
(3/3), S. marcescens (3/3), S. maltophilia (3/3) and M. morganii (1/1). It also correctly
identified blood cultures with the presence of K. oxytoca (3/5), Enterobacter cloacae
(4/6) and Citrobacter freundii (1/1) although under the generic identification of
“Enterobacteriaceae”.
SFC assay only failed to identify K. oxytoca (2/5) and E. cloacae (2/6) in polymicrobial blood
cultures, whereas there was 100% concordance between the two methodologies for these
microorganisms in monomicrobial samples.
SFC assay for the diagnosis of blood infections
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Only 4 positive blood cultures seen to be harbouring Campylobacter jejuni, Bacteroides fra-
gilis, Alcaligenes xylosoxidans and Pseudomonas putida by MALDI-TOF and WalkAway and
were negative by SFC assay since these microorganisms were not included in the assay.
Regarding the detection of yeasts in positive blood cultures, 83% of agreement was found
between MALDI-TOF and SFC. All positive blood culture samples with C. albicans (5/5) iden-
tified by MALDI-TOF were detected by SFC assay and only one sample with C. parapsilosis
was not detected, as expected according to the technical indications of SFC assay.
In sum, 95% of the isolates included in this study were identified by SFC assay. The details
are shown in Table 2.
When antibiotic resistance markers were analyzed for gram-positive microorganisms, SFC
assay detected 52 methicillin resistant Staphylococci (mecA positive), as confirmed by oxacillin
E-test and molecular methods as Xpert MRSA, showing 100% concordance between the two
methodologies. These methicillin resistant Staphylococci were distributed between S. epidermi-
dis (31/52), S. hominis (16/52), S. capitis (2/52), S. aureus (2/52) and S. haemolyticus (1/52).
Vancomycin resistance markers such as vanA or vanB could not be evaluated in positive blood
culture since there was a lack of positive blood cultures with vancomycin resistant Enterococcus
spp.
Table 2. Sensitivity and specificity of SFC assay in bacterial identification from positive blood culture samples.
Organisms isolated form
positive blood cultures
No. of isolates No. of blood culture
correctly identified
Not detected SFC result Sensitivity IC95% Specificity IC95%
Gram-positive Bacteria
Staphylococcus aureus 13 13 S. aureus 100 71–100 100 97–100
Other Staphylococcus spp. 70 70 Staphylococcus sp. 100 93–100 100 97–100
Enterococcus spp. 14 14 Enterococcus sp. 100 73–100 100 97–100
Streptococcus pneumoniae 9 9 S. pneumoniae 100 63–100 100 98–100
Other Streptococcus spp. 8 6 2 Streptococcus sp. 75 35–95 100 97–100
Listeria monocytogenes 1 1 L. monocytogenes 75 35–95 100 97–100
Gram-negative Bacteria
Escherichia coli 56 56 E. coli 100 92–100 100 97–100
Klebsiella pneumoniae 15 15 K. pneumoniae 100 74–100 100 97–100
Klebsiella oxytoca 5 3 2 Enterobacteriaceae 60 17–92 100 97–100
Serratia marcescens 3 3 S. marcescens 100 31–100 100 98–100
Enterobacter cloacae 6 4 2 Enterobacteriaceae 66 24–94 100 98–100
Morganella morganii 1 1 M. morganii 100 5–100 100 98–100
Proteus mirabilis 3 3 Proteus sp. 100 31–100 100 98–100
Pseudomonas aeruginosa 4 4 P. aeruginosa 100 40–100 100 98–100
Acinetobacter baumannii 3 3 A. baumannii 100 31–100 100 98–100
Stenotrophomonas maltophilia 3 3 S. maltophilia 100 31–100 100 98–100
Citrobacter feundii 1 1 Enterobacteriaceae 100 5–100 100 98–100
Fungi
Candida albicans 5 5 C. albicans 100 46–100 97–100
Candida parapsilosis 1 0 1 Negative - -
Not Included
Campylobacter jejuni 1 - 1 Negative
Bacteroides fragilis 1 - 1 Negative
Achromobacter xylosoxidans 1 - 1 Negative
Pseudomonas putida 1 - 1 Negative
Total isolates 225 214 11
Sensitivity and Specificity and 95% Confidence interval of SFC assay.
https://doi.org/10.1371/journal.pone.0177627.t002
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In the study of antibiotic resistance in Gram-negative isolates our standard microbiological
diagnosis methods as cefotaxime E-test combined with inhibitors of class A, B or D ß-lacta-
mases identified the presence of 11 cefotaxime resistant isolates, which 9 were positive for
ESBL production (Table 3) as were confirmed by molecular approach [12]. SFC assay detected
9 samples with genetic resistance determinants which could explain the 81% of cefotaxime
resistant isolates. The main resistance marker associated with cefotaxime resistance identified
by SFC assay was blaCTX, (identified in 4 blood cultures, 1 harbouring E. coli and 3 harbouring
K. pneumonia), followed by blaSHV identified in 2 blood cultures harbouring E. coli. Only 2
blood cultures harbouring E. coli and identified as cefotaxime resistant isolates compatible
with blaAmpC overproduction by our standard microbiological diagnostic protocols and as
were confirmed by molecular approach [13] were not detected by SFC assay since this antibi-
otic resistance determinant is not included in the SFC assay panel.
Regarding evaluation of carbapenemase detection in blood culture by SFC assay, there were
only 4 blood cultures harbouring Pseudomonas aeruginosa carbapenem resistant isolates deter-
mined by imipenem/meroperem E-test and none were positive for carbapenemase production,
as confirmed by molecular approach [13,14] (Table 3). Only 3 blood cultures harbouring A.
baumannii were positive for the blaOXA-51 resistance marker on SFC assay, although these
isolates were not resistant to carbapenems as revealed by imipenem E-test.
Full concordance with previous results were found when 20 randomly selected blood cul-
tures were reanalyzed by SFC (data not shown).
Discussion
SFC assay was seen to be a robust, fast and easy to use tool, which can be easily implemented
in clinical microbiology laboratories since it includes the most common of microorganisms
normally detected in these infections [16–18] and allows the resistance mechanisms of greatest
clinical importance in their treatment to be characterized. When SFC works with the hybri-
Spot HS24 platform, the assay is fully automated and requires a minimal sample manipulation
time, which means that it may be used with positive blood cultures obtained the same work-
day. In this way the results are made available and may be acted upon within the first few
hours of evolution of the patient’s infectious condition.
Although SFC takes a little longer to produce results than does mass spectrometry, it pro-
vides information about the presence of genetic resistance determinants in clinical material.
Because antibiotic resistance is a heterogeneous process involving many factors; for example,
Table 3. Sensitivity and specificity of SFC assay in detection of genetic resistance determinants from positive blood culture samples.
Drug resistant organisms No. of isolates No. of blood culture
correctly identified
Not detected SFC result Sensitivity (%) IC95% Specificity (%) IC95%
Gram-positive Bacteria
MRSAa 2 2 (2) mecA 100 18–100 100 98–100
MRCoNSb 50 50 (50) mecA 100 91–100 100 97–100
VREc 0 - - - -
Gram-negative Bacteria
ESBLd producers 11 9 (2) blaAmpC (7) blaCTX-M, (2) blaSHV 81 47–97 100 98–100
Carbapenemase producers 0 - - - -
a Methicillin Resistant S. aureus.
b Methicillin Resistant Coagulase Negative Staphylococci.
c Vancomycin Resistant Enterococci.
d Extended Spectrum β-Lactamase.
https://doi.org/10.1371/journal.pone.0177627.t003
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according to our results in carbapenem resistance P. aeruginosa the absence of a carbapene-
mase does not imply that it is sensitive to carbapenems since other mechanisms as efflux
pumps and permeability to antibiotic are involved. The lack of concordance between antibiotic
susceptibility and genetic resistance determinants it is one of the main limitations of diagnosis
systems based on detection of genetic resistance determinants like SFC assay.
By the other hand the detection of genetic resistance determinants directly on clinical sam-
ples in early stages of the infection is very useful when it comes to optimizing empirical treat-
ment as quickly as possible or commencing the process of antibiotic de-escalation and will
thus most likely improve the clinical management of patients [19–21]. In addition, rapid diag-
nosis [22,23] will make it possible to reduce the use of certain broad spectrum antibiotics and
help to control the serious problem of antibiotic resistance [24] since it has been reported that
hospitals are excellent compartments for the selection of resistant bacteria due to overuse and
misuse of antimicrobial agents [6].
Compared to other similar systems [9] that are also currently used for diagnosis of positive
blood cultures such as FilmArray BCID [21,25] or Verigene BC-GP and BC-GN [26,27], the
concordance with classical methods based on culture dependent and antibiotic susceptibility
testing is similar [28,29] but the main strength of SFC assay is that it provides a wider panel for
identification of bacteria and genetic resistance determinants for Gram-negative organisms
including the majority of carbapenemases of clinical interest described to date (blaSME,
blaKPC, blaNMC/IMI, blaGES, blaIMP, blaGIM, blaVIM, blaSPM, blaSIM, blaNDM, blaOXA-
23, blaOXA-24, blaOXA-48, blaOXA-51, blaOXA-58) in a single test [30,31]. This is of the
utmost importance bearing in mind the extensive propagation in certain geographical areas of
Gram negative bacteria with this resistance mechanism, in particular Klebsiella pneumoniae
[16].
The use of this type of diagnostic method is revolutionizing the management of these
patients, reducing the time they have to wait before receiving the appropriate antibiotic ther-
apy [9,20]. However, its clinical utility is even greater if the data are managed by a multidisci-
plinary group (stewardship) allowing the results to be applied in an optimal manner [5,32,33].
Antimicrobial stewardship together with this type of diagnostic system also implies significant
financial savings for the healthcare system since hospital and intensive care unit length of stay
is reduced together with total hospital costs and even mortality [22,32].
The increase in antibiotic resistance in our hospitals [34] is an extremely serious public
health problem [2,24]. Due to its complexity, it needs to be approached by multidisciplinary
groups in which clinical microbiology [19] should provide fast diagnostic methods [35–37]
capable of detecting the most prevalent multi-resistant microorganisms [38–40], especially
those that are carbapenemase carriers, which in addition to causing infections that are difficult
to treat may be associated with outbreaks in a hospital setting [41,42]. The system we evaluated
will most likely prove to be a useful tool in the management of patients with bacteraemia and
with the most common fungemia (C. albicans) and also help to control antibiotic resistance
[5,43]. Although SFC detects fungal infections caused by C. albicans, it does not have the
capacity to detect fungemia caused by other Candida spp. as has been shown in pre-clinical
and clinical evaluation of the assay. It provides useful information for the treatment of patients
just a few hours after the blood culture becomes positive [22], which is much quicker than in
the case of classical microbiology, and so will help to improve the use of antibiotics. However
antimicrobial susceptibility testing cannot yet be replaced by molecular systems based on iden-
tification of genetic resistance determinants, as SFC assay due to antibiotic resistance is a het-
erogeneous process involving many factors.
One of the main limitations of our validation study has been the lack of clinical samples
with VRE and carbapenemase producer bacteria. Regarding with these major public health
SFC assay for the diagnosis of blood infections
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issue, where early report of antibiotic resistance would be very helpful for patient management
by clinicians; further interventional studies with patients not only with VRE infections but also
with SARM or carbapenemase producer bacteria should be done with SFC assay in combina-
tion with multidisciplinary group (stewardship) in order to see the SFC assay impact over dif-
ferent patients populations for example in ICU or non-ICU patients.
From our knowledge this is the first study of validation of SFC assay, SFC showed concor-
dance with our standard microbiological diagnostic protocols of 96.2% in monomicrobial and
89.1% in polymicrobial blood cultures and an overall concordance of 92.6%. Although the
results seem promising and better than to other similar diagnosis platforms, further studies
with increased sample size and patient population must be done in order to evaluate other out-
standings aspects that have remained in this work as detection of VRE and carbapenemase
producers bacteria in blood culture.
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